Optimal surgical cytoreduction continues to be an important prognostic variable in patients with ovarian cancer independent of p53 mutational status. Among patients with suboptimal cytoreduction a p53 mutation may offer a survival advantage.
P53, cytoreductive surgery, survival, ovarian cancer
Copyright © David Engle, Hubert Fornalik, Traci Neff, Anna Button, K Collins, Amina Ahmed, David Bender, Susan Lutgendorf, Michael J. Goodheart, 2011
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Engle D, Fornalik H, Neff T, Button A, Collins K, Ahmed A, Bender D, Lutgendorf S, Goodheart M. Comparison of P53 mutation status, primary cytoreductive surgical outcomes, and overall survival in patients with ovarian cancer. Proc Obstet Gynecol. 2011 Jul 28;2(1):Article 10 [2 p.]. https://doi.org/10.17077/2154-4751.1107. Free full text article.